Clover and Ascentage Pharma Announce Clinical Collaboration to Evaluate Recombinant Human TRAIL-Trimer Fusion Protein, SCB-313, in Combination with IAP Antagonist, APG-1387 for the Treatment of Peritoneal Carcinomatosis

by admin
0 comment

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy
WP2Social Auto Publish Powered By :